Vasoactive substances in renal transplantation

Current Opinion in Urology

Volumn 10, Issue 2, 2000, Pages 63-69

  Demetriou, Demetrakis ^a   Wenter, Christian ^a   Watschinger, Bruno ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; DARUSENTAN; ENDOTHELIN; ENDOTHELIN A RECEPTOR ANTAGONIST; NITRIC OXIDE; VASOACTIVE AGENT;

GRAFT REJECTION; GRAFT SURVIVAL; KIDNEY TRANSPLANTATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

ADRENOMEDULLIN; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; ENDOTHELIN-1; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; NITRIC OXIDE; PEPTIDES; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 0034037443     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200003000-00003     Document Type: Review

References (88)

1. 1 Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 299:373-376.
2. 2 Palmer RMJ, Ferrige AG, Moncada S. Release of nitric oxide accounts for the biological activity of endothelium derived relaxing factor. Nature 1987; 327:524-526.
3. 3 Fukuo K, Inoue T, Morimoto S, Nakahashi T, Yasuda O, Kitano S, et al. Nitric oxide mediates cytotoxicity and basic fibroblast growth factor release in cultured vascular smooth muscle cells. J Clin Invest 1995; 95:669-676.
4. 4 Langrehr JM, White DA, Hoffman RA, Simmons RL. Macrophages produce nitric oxide at allograft sites. Ann Surg 1993; 218:159-166.
5. 5 Russell ME, Wallace AF, Wyner LR, Newell JB, Karnovsky MJ. Upregulation and modulation of inducible nitric oxide synthase in rat cardiac allografts with chronic rejection and transplant arteriosclerosis. Circulation 1995; 92:457-464.
6. 6 Cattell V, Smith J, Jansen A, Riveros-Moreno V, Moncada S. Localization of inducible nitric oxide synthase in acute renal allograft rejection in the rat. Transplantation 1994; 58:1399-1402.
7. 7 Agarwal A, Kim Y, Matas AJ, Alam J, Nath KA. Gas-generating systems in acute renal allograft rejection in the rat. Co-induction of heme oxygenase and nitric oxide synthase. Transplantation 1996; 61:93-98.
8. 8 Yang X, Chowdhury N, Cai B, Brett J, Marboe C, Sciacca RR, et al. Induction of myocardial nitric oxide synthase by cardiac allograft rejection. J Clin Invest 1994; 94:714-721.
9. 9 Baylis C, Harton P, Engels K. Endothelial derived relaxing factor controls renal hemodynamics in the normal rat kidney. J Am Soc Nephrol 1994; 1:875-881.
10. 10 Brezis M, Heyman SM, Dinour D, Epstein FH, Rosen S. Role of nitric oxide in renal medullary oxygenation: studies in isolated and intact rat kidneys. J Clin Invest 1991; 88:390-395.
11. 11 Rapoport RM, Draznin MB, Murad F. Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein phosphoryla. Nature 1983; 306:174-176.
12. 12 Garg UC, Hassid A. Inhibition of rat mesangial cell mitogenesis by nitric oxide-generating vasodilators. Am J Physiol 1989; 257:F60-F66.
13. 13 Kuo PC, Schroeder RA. The emerging multifaceted roles of nitric oxide. Ann Surg 1995; 221:220-235.
14. 14 Scott-Burden T, Schini VB, Elizondo E, Junguero DC, Vanhoutte PM. Platelet-derived growth factor suppresses and fibroblast growth factor enhances cytokine-induced production of nitric oxide by cultured smooth muscle cells: effects on cell proliferation. Circulation 1992; 71:1088-1100.
15. 15 Stojanovic T, Gröne HJ, Gieseler RKH, Klanke B, Schlemminger R, Tsikas D, Gröne EF. Enhanced renal allograft rejection by inhibitors of nitric oxide synthase: a nonimmunologic influence on alloreactivity. Lab Invest 1996; 74:496-512.
16. 16 Raij L, Baylis C. Glomerular actions of nitric oxide. Kidney Int 1995; 48:20-32.
17. 17 Winlaw DS, Schyvens CG, Smythe GA, Du ZY, Rainer SP, Lord RS, et al. Selective inhibition of nitric oxide production during cardiac allograft rejection causes a small increase in graft survival. Transplantation 1995; 60:77-82.
18. 18 Worrall NK, Lazenby WD, Misko TP, Lin TS, Rodi CP, Manning PT, et al. Modulation of in vivo alloreactivity by inhibition of inducible nitric oxide synthase. J Exp Med 1995; 181:63-70.
19. 19 Billiar TR. Nitric oxide. Novel biology with clinical relevance. Ann Surg 1995; 221:339-349.
20. 20 Amore A, Gianoglio B, Ghigo D, Peruzzi L, Porcellini MG, Bussolini F, et al. A possible role for nitric oxide in modulating the functional cyclosporine toxicity by arginine. Kidney Int 1995; 47:1507-1514.
21. 21 De Nicola L, Thomson SC, Wead LM, Brown MR, Gabbei FB. Arginine feeding modifies cyclosporine nephrotoxicity in rats. J Clin Invest 1993; 92:1859-1865.
22. 22 Gaston RS, Schlessinger SD, Sanders PW, Barker CV, Curtis JJ, Warnok DG, et al. Cyclosporine inhibits the renal response to L-arginine in human kidney transplant recipients. J Am Soc Nephrol 1995; 5:1426-1433.
23. 23 Andrés A, Morales M, Praga M, Campo C, Lahera R, Garcia-Robles R, et al. L-Arginine reverses the antinatriuretic effect of cyclosporin in renal transplant patients. Nephrol Dial Transplant 1997; 12:1437-1440.
24. 24 Stroes ESG, Lüscher TF, De Groot FG, Koomans HA, Rabelink TJ. Cyclosporine A increases nitric oxide activity in vivo. Hypertension 1997; 29:570-575.
25. 25 Richards AM, Nicholls MG, Lewis L, Lainchbury JG. Adrenomedullin. Clin Sci 1996; 91:3-16.
26. 26 Nakamura M, Yoshida H, Makita S, Arakawa N, Niinuma H, Hiramori K. Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Circulation 1996; 95:1214-1221.
27. 27 Jougasaki M, Wei CM, Aarhys LL, Heublein DM, Sandberg SM, Burnett JCJ. Renal localization and actions of adrenomedullin. Am J Physiol 1995; 268:F657-F663.
28. 28 Ishimitsu T, Nishikimi T, Saito Y, Kitamura K, Eto T, Kangawa K, Matsuo H, et al. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 1994; 94:2158-2161.
29. 29 Geny B, Brandenberger G, Lonsdorfer J, Chakfé N, Haberey P, Piquard F. Circulating adrenomedullin is increased after heart transplantation. Cardiovasc-Res1999; 41:731-736. The first paper reporting on adrenomedullin levels in kidney transplant recipients.
30. 30 Sugo S, Minamino N, Kangawa K, Miyamoto K, Kitamura K, Sakata J, et al. Endothelial cells actively synthesize and secrete adrenomedullin. Biochem Biophys Res Commun 1994; 201:1160-1166.
31. 31 Sugo S, Minamino N, Shoji H, Kangawa K, Kitamura K, Eto T, Matsuo H. Production and secretion of adrenomedullin from vascular smooth muscle cells: augmented production by tumor necrosis factor-alpha. Biochem Biophys Res Commun 1994; 203:719-726.
32. 32 Kangawa K, Matsuo H. Purification and complete amino acid sequence of alpha-human atrial natriutretic polypeptide (alpha-hANP). Biochern Biophys Res Commun 1984; 118:131-139.
33. 33 de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci 1981; 28:89-94.
34. 34 Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1999; 339:321-328.
35. 35 Schulz-Knappe P, Forssmann K, Herbst F, Hock D, Pipkorn R, Forssmann WG. Isolation and structural analysis of 'urodilatin', a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr 1988; 66:752-759.
36. 36 Plum J, Scholtz W, Grabensee B. Atrial natriuretic peptide in renal transplantation. Horm Res 1996; 46:74-82.
37. 37 Nyberg G, Herlitz H, Bjorck S, Karlberg I, Hedner T, Hedner JAD. Acute and long-term changes in plasma levels of atrial natriuretic factor in patients with renal replacement therapy. Transplant Int 1990; 3:195-198.
38. 38 Vinot O, Bialek J, Canaan-Kuhl S, Scandling JDJ, Dafoe D, Alfrey E, Myers BD. Endogenous ANP in postischemic acute renal allograft failure. Am J Physiol 1995; 269:F125-F133.
39. 39 Zuber M, Kiowski W, Huser B, Erne P, Bühler FR, Thiel G. Atrial natriuretic peptide release and volume regulation following kidney transplantation. Clin Nephrol 1993, 40:91-95.
40. 40 Hestin D, Mertes PM, Hubert J, Claudon M, Mejat E, Renoult E, et al. Relationship between blood pressure and renin, angiotensin II and atrial natriuretic factor after renal transplantation. Clin Nephrol 1997; 48:98-103.
41. 41 Coruzzi P, Musiari L, Mossini GL, Ceriati R, Mutti A. The renin-aldosterone system and renal function in kidney transplantation. Clin Nephrol 1994; 41:225-229.
42. 42 Crum R, Fairchild R, Bronsther O, Dominic W, Fernandez DWR, Brown MR. Neuroendocrinology of chronic renal failure and renal transplantation. Transplantation 1991; 52:818-823.
43. 43 Kokot F, Grzeszczak W, Wiecek A, Zukowska-Szczechowska E, Kusmierski S, Szkodny A. Water immersion-induced alterations of plasma atrial natriuretuc peptide, plasma renin activity, plasma aldosterone, and vasoin kidney transplant recipients. Transplant Proc 1989; 21:2052-2055.
44. 44 Hostetter T. Chronic transplant rejection. Kidney Int 1994; 46:266-279.
45. 45 Luke RG. Pathophysiology and treatment of posttransnplant hypertension. J Am Soc Nephrol 1991; 2:37-44.
46. 46 Shihab FS, Bennet WM, Tanner AM, Andoh TF. Angiotensin II blockade decreases TGF-β1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997; 52:660-673.
47. 47 Bresticker M, Nelson J, Huang C, Wolf J, Anderson B. Plasma renin activity in renal transplant patients with hypertension. Am J Hypertens 1991; 4:623-626.
48. 48 Sharma AM, Beige J, Distler A. Role of genetic variants of the renin-angiotensin system in chronic renal allograft injury. Kidney Int 1998; 53:1461-1465.
49. 49 Dubey RK, Jackson EK, Lüscher TF. Nitric oxide inhibits angiotensin II-migration of rat aortic smooth muscle cell: role of cyclic-nucleotides and angiotensin I receptors. J Clin Invest 1995; 96:141-149.
50. 50 Egido J. Vasoactive hormones and renal sclerosis. Kidney Int 1996; 49:578-597.
51. 51 Boulanger CM, Caputo L, Lévy BI. Endothelial AT1-mediated release of nitric oxide decreases angiotensin II contractions in rat carotid artery. Hypertension 1995; 26:752-757.
52. 52 Hennington BS, Zhang H, Miller MT, Granger JP, Reckelhoff JF. Angiotensin II stimulates synthesis of endothelial nitric oxide synthase. Hypertension 1998; 31:283-288.
53. 53 Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension 1992; 19:753-757.
54. 54 Wilcox CS, Welch WJ. Thromboxane mediation of the pressor response to infused angiotensin II. Am J Hypertens 1990; 3:242-249.
55. 55 Barton M, Shaw S, d'Uscio LV, Moreau P, Lüscher TF. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin convertenzyme activity in vivo: role of ET-A-receptors for endothelin regulation. Biochem Biophys Res Commun 1997; 238:861-865.
56. 56 Moreau P, d'Uscio LV, Shaw S, Takase H, Barton M, Lüscher TF. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET-A-receptor antagonist. Circulation 1997; 96:1593-1597.
57. 57 d'Uscio LV, Shaw S, Barton M, Lüscher TF. Losartan but not verapamil inhibits II-induced tissue endothelin-1 increase. Hypertension 1998;31:1305-1310. This study demonstrates that angiotensin receptor blockade reduces endothelin-1 tissue content.
58. 58 Benediktsson H, Chea R, Davidoff A, Paul LC. Antihypertensive drug treatment in chronic allograft rejection in the rat. Effect on structure and function. Transplantation 1996; 62:1634-1642.
59. 59 Amuchastegui SC, Azzollini N, Mister M, Pezzotta A, Perico N, Remuzzi G. Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J Am Soc Nephrol 1998; 9:1948-1955.
60. 60 Castillo J, Berrazueta JR, Herrera L, Val-Bernal J, Gómez J, Sánchez MJ, et al. Nitric oxide production during the hyperacute vascular rejection. J Surg Res 1996; 63:375-380.
61. 61 Barnas U, Schmidt A, Haas M, Oberbauer R, Mayer G. The effects of prolonged angiotensin-converting enzyme inhibition on excretory kidney function and proteinuria in renal allograft recipients with chronic progressive transplant failure. Nephrol Dial Transplant 1996; 11:1822-1824.
62. 62 Mourad G, Ribstein J, Mimran A. Converting- enzyme inhibitor versus calcium antagonist in cyclosporine treated renal transplants. Kidney Int 1993; 43:419-425.
63. 63 Rell K, Linde J, Morzycka-Michalik M, Gaciong Z, Lao M. Effect of enalapril on proteinuria after kidney transplantation. Transpl Int 1993; 6:213-217.
64. 64 Traindl O, Falger S, Reading S, Banyai M, Liebisch B, Giesinger J, et al. The effects of lisinopril on renal function in proteinuric renal transplant recipients. Transplantation 1993; 55:1309-1313.
65. 65 Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331:1286-1292.
66. 66 Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell response to angiotensin II. J Clin Invest 1993; 91:2268-2274.
67. 67 Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93:2431-2437.
68. 68 Mason J, Muller-Schweinitzer E, Dupont M, Casellas D, Mihatsch M, Moore L, Kaskel F. Cyclosporine and the renin-angiotensin system. Kidney Int 1991; 39:28-32.
69. 69 Lee DB. Cyclosporine and the renin-angiotensin axis. Kidney Int 1997; 52:248-260.
70. 70 Campistol JM, Inigo P, Jimenez W, Lario S, Clesca PH, Oppenheimer F, Rivera F. Losartan decreases plasma levels of TGF-beta 1 in transplant patients with allograft nephropathy. Kidney Int 1999; 56:714-719. Small but interesting report which shows that profibrotic substances in the plasma of transplant patients can be lowered by inhibition of angiotensin II action.
71. 71 Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415.
72. 72 Watschinger B, Sayegh MH. Endothelin in organ transplantation. Am J Kidney Dis 1996; 27:151-161.
73. 73 Hahn AWA, Resink TJ, Scott-Burden T, Powell J, Dohi Y, Bühler FR. Stimulation of endothetin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function. Cell Regul 1990; 1:649-659.
74. 74 Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348:730-732.
75. 75 Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990; 348:732-735.
76. 76 Martin ER, Brenner BM, Ballermann BJ. Heterogeneity of cell surface endothelin receptors. J Biol Chem 1990; 265:14044-14049.
77. 77 Lin HY, Kaji EH, Winkel GK, Ives HE, Lodisch HF. Cloning and functional expression of a vascular smooth muscle endothelin-1 receptor. Proc Nat Acad Sci USA 1989; 88:3185-3189.
78. 78 Blancho G, Moreau JF, Chabanne D, Chatenoud L, Soulillou JP. HILDA/LIF, G.CSF, IL-1B, IL-6, and TNF alpha production during acute rejection of human kidney allografts. Transplantation 1993; 56:597-602.
79. 79 Vierhapper H, Wagner O, Nowotny P, Waldhäusl W. Effect of endothelin-1 in man. Circulation 1990; 81:1415-1418.
80. 80 King AJ, Brenner BM, Anderson S. Endothelin: a potent renal and systemic vasoconstrictor peptide. Am J Physiol 1989; 256:F1051-F1058.
81. 81 Watschinger B, Vychytil A, Schuller M, Hartter E, Traindl O, Pohanka E, et al. Pathophysiological role of endothelin in acute vascular rejection after renal transplantation. Transplantation 1991; 52:743-746.
82. 82 Watschinger B, Vychytil A, Attar M, Wagner D, Schuller M, Hartter E, Ulrich W. Pattern of endothelin immunostaining during rejection episodes after kidney transplantation. Clin Nephrol 1994; 41:86-93.
83. 83 Yamakado M, Hirata Y, Matsuoka H, Sugimoto T. Pathophysiological role of endothelin in renal transplantation. J Cardiovasc Pharmacol 1991; 17(Suppl. 7):S477-S479.
84. 84 Mouquet C, Carayon A, Ourahma S, Chartier-Kastler E, Masson F, Bitker MO, Viars P. Course of plasma endothelin levels during acute rejection in kidney transplantation. Transplant Proc 1994; 26:279.
85. 85 Simonson MS, Emancipator SN, Knauss T, Hricik DE. Elevated neointimal in transplantation-associated arteriosclerosis of renal allograft . Kidney Int 1998; 54:960-971. Demonstration of endothelin-1 in the wall of arteriosclerotic vessels of renal allografts.
86. 86 Watschinger B, Sayegh MH, Hancock WW, Russell ME. Upregulation of endothelin-1 mRNA and peptide expression in rat cardiac allografts with rejection and arteriosclerosis. Am J Pathol 1995; 146:1-8.
87. 87 Orth SR, Odoni G, Amann K, Strzelczyk P, Raschack M, Ritz E. The ET(A) blocker LU 135252 prevents chronic transplant nephropathy in the to Lewis' model. J Am Soc Nephrol 1999; 10:387-391. The authors identify endothelin receptor antagonists as therapeutic tool in preventing allograft nephropathy in the rat.
88. 88 Braun C, Conzelmann T, Vetter S, Schaub M, Back WE, Yard B, et al. Prevention of chronic renal allograft rejection in rats with an oral endothelin A antagonist. Transplantation 1999; 68:739-743. In accordance with [87], this report stresses the role of endothelin receptor antagonists in chronic renal allograft nephropathy.